LLY0 Stock Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. More details

LLY0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	4/6
Financial Health	3/6
Dividends	3/6

Rewards

Trading at 46.2% below our estimate of its fair value

Earnings are forecast to grow 29.8% per year

Earnings grew by 67.8% over the past year

Risk Analysis

High level of non-cash earnings

Debt is not well covered by operating cash flow

Volatile share price over the past 3 months compared to the German market

My Notes

Capture your thoughts, links and company narrative

Eli Lilly and Company Competitors

Merck KGaA

XTRA:MRK

€60.1b

Dermapharm Holding

XTRA:DMP

€2.0b

Novo Nordisk

CPSE:NOVO B

DKK 2.6t

Johnson & Johnson

NYSE:JNJ

US$347.8b

Price History & Performance

Summary of share price highs, lows and changes for Eli Lilly
Historical stock prices
Current Share Price	US$19.20
52 Week High	US$25.20
52 Week Low	US$17.80
Beta	0.40
1 Month Change	-6.80%
3 Month Change	-11.93%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-1.50%

Recent updates

Shareholder Returns

	LLY0	DE Pharmaceuticals	DE Market
7D	-6.8%	-2.5%	-2.6%
1Y	n/a	-15.6%	6.9%

Return vs Industry: Insufficient data to determine how LLY0 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LLY0 performed against the German Market.

Price Volatility

Is LLY0's price volatile compared to industry and market?
LLY0 volatility
LLY0 Average Weekly Movement	10.4%
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: LLY0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: LLY0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1876	43,000	Dave Ricks	www.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

Eli Lilly and Company Fundamentals Summary

How do Eli Lilly's earnings and revenue compare to its market cap?
LLY0 fundamental statistics
Market cap	€662.56b
Earnings (TTM)	€8.02b
Revenue (TTM)	€39.16b

82.6x

P/E Ratio

16.9x

P/S Ratio

Is LLY0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LLY0 income statement (TTM)
Revenue	US$40.86b
Cost of Revenue	US$7.80b
Gross Profit	US$33.06b
Other Expenses	US$24.69b
Earnings	US$8.37b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 06, 2025

Earnings per share (EPS)	9.30
Gross Margin	80.91%
Net Profit Margin	20.48%
Debt/Equity Ratio	218.1%

How did LLY0 perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

54%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 21:21
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eli Lilly and Company is covered by 63 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Ishan Majumdar	Baptista Research
Alistair Campbell	Berenberg

LLY0 Stock Overview

Rewards

Risk Analysis

Eli Lilly and Company Competitors

XTRA:MRK

€60.1b

XTRA:DMP

€2.0b

CPSE:NOVO B

DKK 2.6t

NYSE:JNJ

US$347.8b

Price History & Performance

Recent News & Updates

U.S. Food and Drug Administration Approves Eli Lilly and Company's Zepbound (Tirzepatide) as the First and Only Prescription Medicine for Moderate-To-Severe Sleep Apnea in Adults with Obesity

Eli Lilly and Company's Kisunla™ (donanemab-azbt) Approves in China for the Treatment of Early Symptomatic Alzheimer's Disease

Eli Lilly and Company's Omvoh Recommends by CHMP for Approval in the European Union for Adults with Moderate to Severely Active Crohn's Disease

Eli Lilly and Company Announces Results from the Phase 3 Ember-3 Study of Imlunestrant

Eli Lilly and Company Declares Dividend for the First Quarter of 2025, Payable on March 10, 2025

Eli Lilly and Company (NYSE:LLY) announces an Equity Buyback for $15,000 million worth of its shares.

Recent updates

U.S. Food and Drug Administration Approves Eli Lilly and Company's Zepbound (Tirzepatide) as the First and Only Prescription Medicine for Moderate-To-Severe Sleep Apnea in Adults with Obesity

Eli Lilly and Company's Kisunla™ (donanemab-azbt) Approves in China for the Treatment of Early Symptomatic Alzheimer's Disease

Eli Lilly and Company's Omvoh Recommends by CHMP for Approval in the European Union for Adults with Moderate to Severely Active Crohn's Disease

Eli Lilly and Company Announces Results from the Phase 3 Ember-3 Study of Imlunestrant

Eli Lilly and Company Declares Dividend for the First Quarter of 2025, Payable on March 10, 2025

Eli Lilly and Company (NYSE:LLY) announces an Equity Buyback for $15,000 million worth of its shares.

Eli Lilly and Company Announces Topline Results from the SURMOUNT-5 Phase 3B Open-Label Randomized Clinical Trial

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Announces Positive Phase 2 Results for muvalaplin

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.